Literature DB >> 31520748

PI3K/AKT/mTOR pathway inhibitors in triple-negative breast cancer: a review on drug discovery and future challenges.

Mohammad A Khan1, Vineet K Jain2, Md Rizwanullah3, Javed Ahmad4, Keerti Jain5.   

Abstract

Triple-negative breast cancer (TNBC) is a highly malignant subtype of breast cancer associated with poor prognosis. Although conventional chemotherapy regimens have shown some effectiveness in early TNBC cases, the outcome in advanced stages is poor. The PI3K/AKT/mTOR pathway is one of the important and active pathways involved in chemoresistance and survival of TNBC. This pathway is speculated to play an important part in malignant transformation and has been considered as a potential molecular target for the design of therapeutic agents to treat TNBC. This review discusses the potentials and drug discovery perspectives of PI3K/AKT/mTOR as a therapeutic target for effective management of TNBC with anticipated challenges.
Copyright © 2019 Elsevier Ltd. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 31520748     DOI： 10.1016/j.drudis.2019.09.001

Source DB:  PubMed          Journal:  Drug Discov Today        ISSN： 1359-6446            Impact factor:   7.851


  48 in total

Review 1.  RETRACTED ARTICLE: Roles of the PI3K/AKT/mTOR signalling pathways in neurodegenerative diseases and tumours.

Authors:  Fei Xu; Lixin Na; Yanfei Li; Linjun Chen
Journal:  Cell Biosci       Date:  2020-04-01       Impact factor: 7.133

Review 2.  Molecular targets and therapeutics in chemoresistance of triple-negative breast cancer.

Authors:  Arijit Nath; Soham Mitra; Tanuma Mistry; Ranita Pal; Vilas D Nasare
Journal:  Med Oncol       Date:  2021-11-23       Impact factor: 3.064

3.  Moving Towards Targeted Therapies for Triple-Negative Breast Cancer.

Authors:  Jodi A Kagihara; Elena Shagisultanova; Anosheh Afghahi; Jennifer R Diamond
Journal:  Curr Breast Cancer Rep       Date:  2021-05-04

Review 4.  Myricetin-induced apoptosis in triple-negative breast cancer cells through inhibition of the PI3K/Akt/mTOR pathway.

Authors:  Preeti Sharma; Mohammad Ahmed Khan; Abul Kalam Najmi; Shubhra Chaturvedi; Mohd Akhtar
Journal:  Med Oncol       Date:  2022-10-08       Impact factor: 3.738

5.  The impact of cycleanine in cancer research: a computational study.

Authors:  Ogochukwu Ngozi Nwaefulu; Nizar A Al-Shar'i; Josephine Omonkhelin Owolabi; Sreenivasa Rao Sagineedu; Lim Chee Woei; Lam Kok Wai; Mohammad Kaisarul Islam; Sivaraman Jayanthi; Johnson Stanslas
Journal:  J Mol Model       Date:  2022-10-04       Impact factor: 2.172

6.  Integrative multiplatform-based molecular profiling of human colorectal cancer reveals proteogenomic alterations underlying mitochondrial inactivation.

Authors:  Wei Zhang; Donge Tang; Liewen Lin; Tingting Fan; Ligang Xia; Wanxia Cai; Weier Dai; Chang Zou; Lianghong Yin; Yong Xu; Yong Dai
Journal:  Am J Cancer Res       Date:  2021-06-15       Impact factor: 6.166

7.  C-reactive protein promotes tongue squamous cell carcinoma chemoresistance by inhibiting the activation of caspase-3/9 via the CD64/AKT/mTOR pathway.

Authors:  Shenglin Wang; Qinchao Chen; Xiaodong Yan; Meng Cao; Zhigang Wang
Journal:  Hum Cell       Date:  2021-05-21       Impact factor: 4.174

8.  The Marine Natural Product Furospinulosin 1 Induces Apoptosis in MDA-MB-231 Triple Negative Breast Cancer Cell Spheroids, But Not in Cells Grown Traditionally with Longer Treatment.

Authors:  Esther A Guzmán; Tara P Pitts; Priscilla L Winder; Amy E Wright
Journal:  Mar Drugs       Date:  2021-04-28       Impact factor: 5.118

9.  Signal transduction pathways involved in dopamine D2 receptor-evoked emesis in the least shrew (Cryptotis parva).

Authors:  Louiza Belkacemi; Weixia Zhong; Nissar A Darmani
Journal:  Auton Neurosci       Date:  2021-04-10       Impact factor: 2.355

10.  Targeting a cell surface vitamin D receptor on tumor-associated macrophages in triple-negative breast cancer.

Authors:  Wadih Arap; Renata Pasqualini; Fernanda I Staquicini; Amin Hajitou; Wouter Hp Driessen; Bettina Proneth; Marina Cardó-Vila; Daniela I Staquicini; Christopher Markosian; Maria Hoh; Mauro Cortez; Anupama Hooda-Nehra; Mohammed Jaloudi; Israel T Silva; Jaqueline Buttura; Diana N Nunes; Emmanuel Dias-Neto; Bedrich Eckhardt; Javier Ruiz-Ramírez; Prashant Dogra; Zhihui Wang; Vittorio Cristini; Martin Trepel; Robin Anderson; Richard L Sidman; Juri G Gelovani; Massimo Cristofanilli; Gabriel N Hortobagyi; Zaver M Bhujwalla; Stephen K Burley
Journal:  Elife       Date:  2021-06-01       Impact factor: 8.140
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.